Related Experiment Video
Updated: Aug 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Bis(pivaloyloxymethyl) thymidine 5'-phosphate is a cell membrane-permeable precursor of thymidine 5'-phosphate in
Saeed R Khan1, Billie Nowak, William Plunkett
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. khansa@jhmi.edu
Abstract:
Bis(pivaloyloxymethyl) thymidine 5-phosphate (POM(2)-dTMP) has been investigated as a membrane-permeable prodrugs of dTMP. The growth inhibitory activity of POM(2)-TMP has been compared with thymidine (TdR) in wild type CCRF CEM cells (CEM) and a strain that lacks TdR kinase (CEM tk-). After 72 h incubation at 37 degrees C, TdR showed significant antiproliferative activity (IC(50)=27 microM) against CEM cells but was weakly effective (IC(50)=730 microM) against the mutant cell line. By comparison, bis(pivaloyloxymethyl) thymidine 5'-monophosphate (POM(2)-dTMP) was equally inhibitory (IC(50)=5 microM) to both cell lines. The growth inhibitory effects were reversed by deoxycytidine. Cellular [methyl-(3)H]dTTP pools increased linearly over 2h during incubation of CEM or CEM tk- with 5 microM POM(2)-[methyl-(3)H]dTMP. The incorporation of [methyl-(3)H]TdR into HClO(4)-insoluble cell residue by CEM tk- was <0.1% that of CEM and did not increase over 1h. In contrast, CEM tk- incorporated radioactivity from POM(2)-dTMP into acid insoluble residue at a rate 59% that of CEM. These results demonstrate that POM(2)-dTMP can penetrate into cells and serve as a source of dTMP.
Insights
Bis(pivaloyloxymethyl) thymidine 5-phosphate (POM(2)-dTMP) effectively inhibits cell growth in both normal and thymidine kinase-deficient cells. This membrane-permeable prodrug serves as a viable source of thymidine monophosphate (dTMP).
Area of Science:
- Pharmacology
- Cell Biology
- Biochemistry
Background:
- Thymidine (TdR) is crucial for DNA synthesis but requires thymidine kinase (TK) for activation.
- TK-deficient cells exhibit resistance to TdR, limiting its therapeutic applications.
- Developing membrane-permeable prodrugs of thymidine monophosphate (dTMP) is essential for overcoming TK deficiency.
Purpose of the Study:
- To evaluate bis(pivaloyloxymethyl) thymidine 5-phosphate (POM(2)-dTMP) as a prodrug of dTMP.
- To compare the growth inhibitory activity of POM(2)-dTMP and TdR in wild-type and TK-deficient CCRF CEM cells.
- To investigate the mechanism of POM(2)-dTMP uptake and its conversion to dTMP.
Main Methods:
- Cell culture of wild-type (CEM) and TK-deficient (CEM tk-) CCRF CEM cells.
- Antiproliferative assays to determine IC(50) values for POM(2)-dTMP and TdR.
- Radiolabeling studies using [methyl-(3)H]dTMP and [methyl-(3)H]TdR to assess cellular uptake and incorporation.
Main Results:
- POM(2)-dTMP exhibited significant and equal growth inhibition (IC(50)=5 microM) in both CEM and CEM tk- cells.
- TdR showed potent activity against CEM cells (IC(50)=27 microM) but weak activity against CEM tk- cells (IC(50)=730 microM).
- CEM tk- cells incorporated radioactivity from POM(2)-dTMP into acid-insoluble residue at a substantial rate, unlike with TdR.
Conclusions:
- POM(2)-dTMP effectively bypasses the requirement for thymidine kinase.
- This prodrug demonstrates efficient cellular penetration and serves as a valuable source of dTMP.
- POM(2)-dTMP holds potential as a therapeutic agent for conditions involving TK deficiency.
Related Concept Videos
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Negative Regulator Molecules
Positive Regulator Molecules
Positive Regulator Molecules
Biosynthesis of Nucleic Acids

